Active monitoring method and system for adverse drug reaction

Abstract

The invention discloses an active monitoring method and system for adverse drug reactions, and belongs to the technical field of drug monitoring, and the method comprises the steps: generating a first mapping table based on the corresponding relation between drug data and historical adverse reaction data, and constructing a first retrieval library; a second mapping table is generated based on the corresponding relation between the historical adverse reaction data and the historical clinical sign data, and a second retrieval library is constructed; acquiring drug use data, adverse reaction data and clinical sign data of the corresponding patient in real time; retrieving a second retrieval library based on the real-time clinical sign data, and obtaining corresponding adverse reaction data in combination with the first mapping table; retrieving a first retrieval library based on the adverse reaction data, and matching the retrieved drug data with the real-time drug use data to obtain a drug matching result; and generating an adverse reaction monitoring log and uploading the log to a hospital information system. According to the scheme, different corresponding retrieval tables are constructed to match the real-time data, so that the monitoring efficiency of the adverse drug reaction can be improved.

Description

Technical Field

[0001] The present invention belongs to the technical field of drug monitoring, and in particular relates to an active monitoring method and system for adverse drug reactions. Background Art

[0002] Adverse drug reaction monitoring is an important part of ensuring the safety of patients' medication, which is directly related to the quality of medical care and the health of patients. With the continuous advancement of medical technology and the increasing number of drug types, the monitoring of adverse drug reactions has become increasingly complex and important. However, the existing adverse reaction monitoring is mainly achieved through manual observation and recording by doctors or pharmacists during the diagnosis and treatment process, which has many limitations. Manual monitoring relies on the professional knowledge and experience of medical staff, and is prone to subjective judgment bias and omissions, making it difficult to ensure the comprehensiveness and accuracy of monitoring. Secondly, due to the limited medical resources and the large number of patients, it is difficult for medical staff to conduct comprehensive and continuous monitoring of all medication patients, resulting in a lag in the discovery and reporting of adverse reactions. Furthermore, most of the existing monitoring systems lack real-time and intelligence, and cannot collect and analyze patients' medication information and adverse reaction data in a timely and automatic manner, resulting in low efficiency in monitoring adverse drug reactions. A more efficient, accurate and real-time adverse drug reaction monitoring method is urgently needed to ensure patients' medication safety. Summary of the invention

[0003] The purpose of the present invention is to solve the problem of low efficiency of the drug adverse reaction monitoring method in the prior art, and to provide an active monitoring method and system for drug adverse reactions. By constructing a first mapping table and a first retrieval library based on a drug database and historical adverse reaction data, and constructing a second mapping table and a second retrieval library based on historical adverse reaction data and historical clinical characteristic data, the hospital information system is combined to safely access real-time data, and the corresponding relationship between the real-time adverse reaction data, the real-time clinical characteristic data and the real-time drug use data is searched and found through the accessed real-time data set, the first retrieval library and the second retrieval library, thereby realizing real-time active monitoring of drug adverse reactions and improving the efficiency of drug adverse reaction monitoring.

[0004] In order to achieve the above object, the present invention adopts the following technical solutions: According to a first aspect of the present invention, there is provided a method for actively monitoring adverse drug reactions, comprising the following steps: S1, generating a first mapping table based on the correspondence between drug data and historical adverse reaction data in a drug database and constructing a first search library based on the first mapping table; S2, generating a second mapping table based on the correspondence between the historical adverse reaction data and the historical clinical sign data, and constructing a second search library based on the second mapping table; S3, initiating an access request to the hospital information system based on the access permission information, and obtaining the corresponding patient's real-time drug usage data, real-time adverse reaction data, and real-time clinical sign data from the hospital information system after the request is approved; S4, searching the second search library based on the real-time clinical sign data, and acquiring corresponding adverse reaction data according to the clinical sign data obtained by the search and the first mapping table; S5. Search the first search database based on the adverse reaction data, and match the retrieved drug data with the real-time drug usage data to obtain a drug matching result; S6. Generate an adverse reaction monitoring log based on the drug matching results and upload it to the hospital information system.

[0005] In the above technical solution, by constructing a first mapping table based on drug data and adverse reaction data, and a second mapping table based on historical adverse reaction data and clinical sign data, it is possible to quickly search and match based on real-time data, thereby timely discovering potential adverse reactions and improving the efficiency and accuracy of monitoring. By real-time monitoring and proactively reporting adverse reactions, it is possible to intervene and deal with possible problems more quickly, thereby effectively reducing patient harm caused by adverse drug reactions and enhancing patient medication safety.

[0006] Preferably, S1 comprises the following steps: S11. Obtain historical adverse reaction data corresponding to all drug types in the drug database; S12, determining the drug ID corresponding to each drug type, and performing data cleaning on the historical adverse reaction data to extract the corresponding adverse reaction type; S13, constructing a first mapping table based on the correspondence between the drug ID and the adverse reaction type; S14. Construct a first search library based on the first mapping table.

[0007] In the above technical scheme, by determining the drug ID corresponding to each drug type, performing data cleaning on the historical adverse reaction data, extracting the corresponding adverse reaction type, and effectively removing redundant and erroneous data, a first mapping table is constructed based on the correspondence between the drug ID and the adverse reaction type, ensuring the accuracy and uniqueness of the mapping relationship, and a first retrieval library is constructed based on the first mapping table, so that in the subsequent monitoring process, the corresponding drug information can be quickly retrieved according to the adverse reaction type, which not only improves the retrieval efficiency, but also reduces the system resource consumption, which helps to select drugs more carefully and accurately during the medication process and reduce the occurrence of adverse reactions.

[0008] Preferably, S1 comprises the following steps: S21, obtaining historical clinical sign data corresponding to each adverse reaction type in the historical adverse reaction data; S22, performing data cleaning on the historical clinical sign data to extract corresponding clinical sign types; S23, constructing a second mapping table based on the correspondence between the adverse reaction type and the clinical sign type; S24: construct a second search library based on the second mapping table.

[0009] In the above technical solution, by obtaining the historical clinical sign data corresponding to each adverse reaction type in the historical adverse reaction data, clinical signs closely related to adverse reactions can be identified, which helps to give early warning when patients show similar signs, so as to take preventive measures and reduce the occurrence of adverse reactions. By cleaning the historical clinical sign data and extracting the corresponding clinical sign types, the accuracy and consistency of the data are ensured. Constructing a second mapping table based on the correspondence between adverse reaction types and clinical sign types helps doctors better understand and determine the occurrence mechanism of adverse reactions, so as to formulate more effective prevention and treatment strategies. Constructing a second retrieval library based on the second mapping table enables doctors to quickly retrieve adverse reaction information related to current clinical signs when facing patients, so as to more accurately assess the patient's risks and formulate personalized treatment plans, thereby optimizing the clinical decision-making process.

[0010] Preferably, S3 comprises the following steps: S31, generating corresponding access permission information based on the monitoring period and monitoring object information; S32, submitting an access application to the hospital information system based on the access permission information, and having the hospital information system review the access permission information. If the review is passed, access to the data server of the hospital information system is allowed; if the review is not passed, executing S31; S33. Acquire real-time drug usage data, real-time adverse reaction data and real-time clinical sign data from the data server of the hospital information system.

[0011] In the above technical solution, by combining the monitoring cycle and the monitoring object information to generate the corresponding access permission information, it is ensured that only users or systems with legal permissions can access the data server of the hospital information system. The permission-based access control mechanism effectively prevents unauthorized access and data leakage, and enhances the security of data access. Based on the access permission information, an access application is submitted to the hospital information system, and the access permission information is reviewed by the hospital information system to ensure the compliance of data access. Real-time drug use data, real-time adverse reaction data and real-time clinical sign data are obtained from the data server of the hospital information system. The acquisition of real-time data can help medical institutions to detect potential problems in a timely manner and take measures, and also ensure the accuracy and reliability of the data.

[0012] Preferably, the S31 comprises the following steps: S311, setting a monitoring period based on the monitoring start time and the monitoring end time; S312, determining the basic identity information corresponding to the monitored object, and setting the corresponding access permission level based on the basic identity information; S313, generating an access permission information identifier based on the monitoring period, the basic identity information and the access permission level; S314: Perform hash encoding on the authority information identifier based on a hash algorithm to obtain an encrypted information identification code.

[0013] In the above technical solution, the corresponding access permission level is set by determining the basic identity information of the monitored object, ensuring that only users or systems with corresponding permissions can access the relevant data. The permission information identifier is encrypted using a hash algorithm to further enhance the security of access control and prevent the leakage and tampering of permission information. Based on the monitoring cycle, basic identity information and access permission level, the permission information identifier is generated and hashed to obtain an encrypted information identification code, which can enable the access and use of data to be accurately recorded and tracked, and can be quickly located through the encrypted information identification code to ensure the traceability and auditability of the data. The generated encrypted information identification code can be used as a credential for accessing the medical information system, and information sharing and interaction can be more efficient while ensuring the security of data access.

[0014] Preferably, the S32 comprises the following steps: S321, sending the encrypted information identification code to the hospital information system through a corresponding communication protocol; S322, the hospital information system receives the encrypted information identification code and performs hash decoding to obtain an authority information identifier; S323, extracting the monitoring period, basic identity information and authority information from the authority information identifier; S324, review the monitoring period and basic identity information in combination with the authority information. If the review is passed, access the data server of the hospital information system. If the review is not passed, execute S31.

[0015] In the above technical solution, the encrypted information identification code is sent through the corresponding communication protocol to ensure the security and integrity of the data transmission process. Since the encrypted information identification code is hash-encoded, even if it is intercepted during the transmission process, the original permission information cannot be easily obtained, thereby effectively preventing the leakage of sensitive information. After receiving the encrypted information identification code, the hospital information system performs hash decoding to quickly restore the original permission information identifier. The decoding process is more efficient than the traditional audit method and reduces the possibility of manual intervention and errors. The monitoring cycle and basic identity information are audited in combination with the permission information to ensure that only users or systems that meet the requirements can obtain the permission to access the hospital information system data server, thereby improving the accuracy of the permission audit. If the audit fails, the access permission information is regenerated to ensure that it can self-recover and continue to operate normally in the face of errors or abnormal situations, thereby improving the reliability and stability of the system.

[0016] Preferably, S4 comprises the following steps: S41, performing data cleaning on the real-time clinical sign data to extract corresponding real-time clinical sign types; S42, matching the real-time clinical sign type with all clinical sign types in the second search library to obtain a corresponding clinical sign type; S43: searching for the adverse reaction type corresponding to the clinical sign type based on the clinical sign type obtained by matching and combining the second mapping table.

[0017] In the above technical solution, by performing data cleaning on the real-time clinical sign data to extract the corresponding real-time clinical sign type, invalid, erroneous or duplicate data can be removed, the accuracy and reliability of subsequent analysis can be ensured, and the efficiency and accuracy of data processing can be improved. By matching the real-time clinical sign type with all clinical sign types in the second search library, the corresponding clinical sign type can be quickly found through an efficient search algorithm. Based on the matched clinical sign type, the corresponding adverse reaction type is searched in combination with the second mapping table, which realizes the precise association between clinical signs and adverse reactions, and helps to accurately judge the adverse reactions that may occur in patients, so as to take corresponding preventive and treatment measures.

[0018] Preferably, S5 comprises the following steps: S51, matching the adverse reaction type found with all adverse reaction types in the first search library to obtain a corresponding adverse reaction type; S52, searching for drug data corresponding to the adverse reaction type based on the adverse reaction type obtained by matching and combining with the first mapping table; S53: Match the found drug data with the real-time drug ID in the real-time drug usage data to obtain a corresponding drug ID.

[0019] In the above technical solution, by matching the adverse reaction types obtained through the search with all the adverse reaction types in the second search library, the accuracy and uniqueness of adverse reaction identification are ensured, which helps medical institutions to accurately understand the types of adverse reactions that patients may encounter and provide a strong basis for subsequent treatment and preventive measures. Based on the matched adverse reaction types, the corresponding drug data is searched in combination with the first mapping table to achieve a rapid association between adverse reactions and drugs that may cause the adverse reactions, which can quickly locate problematic drugs and provide important information for subsequent drug safety assessments and risk controls. The drug data obtained through the search is matched with the real-time drug ID in the real-time drug usage data to obtain the corresponding drug ID, which enables monitoring of real-time drug usage, helps to promptly discover and deal with problems in drug usage, and ensures the safety and effectiveness of patient medication.

[0020] Preferably, S6 comprises the following steps: S61, determining the relevant drug ID, adverse reaction type and clinical sign type according to the drug matching result; S62. Determine the severity of the adverse reaction type; S63, generating a corresponding adverse reaction monitoring log in combination with the drug ID, the adverse reaction type and the clinical sign type; S64. Annotate the adverse reaction monitoring log based on the severity, and upload the annotated adverse reaction monitoring log to a hospital information system.

[0021] In the above technical solution, the adverse reaction monitoring log is generated by combining the drug ID, adverse reaction type and clinical sign type, which enhances the transparency and traceability of adverse reaction monitoring and helps to respond quickly and effectively when adverse reaction events occur. The adverse reaction monitoring log is marked based on the severity and uploaded to the hospital information system. Medical institutions can adjust treatment plans and optimize drug use rules based on the adverse reaction monitoring log, which helps medical institutions establish a more complete drug vigilance and risk management system to ensure the safety and effectiveness of patients' medication.

[0022] According to a second aspect of the present invention, there is provided a system for monitoring adverse drug reactions, comprising: A first search library construction module, used to generate a first mapping table based on the correspondence between drug data and historical adverse reaction data in the drug database and to construct a first search library based on the first mapping table; A second search library construction module, used to generate a second mapping table based on the correspondence between the historical adverse reaction data and the historical clinical sign data and to construct a second search library based on the second mapping table; A data access request module is used to initiate an access request to the hospital information system based on the access permission information, and obtain the corresponding patient's real-time drug usage data, real-time adverse reaction data and real-time clinical sign data from the hospital information system after the request is approved; a first adverse reaction retrieval module is used to search the second retrieval library based on the real-time clinical sign data, and obtain the corresponding adverse reaction data according to the clinical sign data obtained by the retrieval combined with the first mapping table; A second adverse reaction retrieval module is used to search the first retrieval library based on the adverse reaction data, and match the retrieved drug data with the real-time drug usage data to obtain a drug matching result; The monitoring log construction module is used to generate adverse reaction monitoring logs based on drug matching results and upload them to the hospital information system.

[0023] The beneficial effects of the present invention are as follows: by performing data retrieval through the constructed mapping table and retrieval library, possible adverse reaction types and their corresponding drugs can be matched quickly and accurately, thus improving the accuracy of monitoring and the efficiency of data processing and retrieval. By setting access permission information and the corresponding audit mechanism, it is ensured that only users with corresponding permissions can access the data of the hospital information system, thus improving the security of data access. The access permission information is transmitted by means of hash encoding and decoding, thereby enhancing the security of the information transmission process. The generated adverse reaction monitoring log records in detail information such as drug ID, adverse reaction type, clinical sign type and severity, and can better monitor the adverse reactions of drugs. The annotated adverse reaction monitoring log can more intuitively reflect the severity of adverse reactions, making it easier for hospitals to take corresponding countermeasures.

[0024] The above invention content is only an overview of the technical solution of the present invention. In order to more clearly understand the technical means of the present invention, it can be implemented according to the contents of the specification. In order to make the above and other purposes, features and advantages of the present invention more obvious and easy to understand, the specific implementation methods of the present invention are listed below. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] Other features, objects and advantages of the present invention will become more apparent by reading the detailed description of non-limiting embodiments made with reference to the following drawings. The drawings are only for the purpose of illustrating preferred embodiments and are not to be considered as limiting the present invention. Also, the same reference symbols are used throughout the drawings to represent the same parts.

[0026] Figure 1 A flowchart of a method for actively monitoring adverse drug reactions disclosed in an embodiment of the present invention; Figure 2 The present invention is a schematic diagram of the structure of an active monitoring system for adverse drug reactions disclosed in an embodiment of the present invention. DETAILED DESCRIPTION

[0027] In order to make the objectives, technical solutions and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with the accompanying drawings and embodiments. It should be understood that the specific implementation method described herein is only an optimal embodiment of the present invention, which is only used to explain the present invention and does not limit the scope of protection of the present invention. All other embodiments obtained by ordinary technicians in this field without making creative work are within the scope of protection of the present invention.

[0028] Before discussing the exemplary embodiments in more detail, it should be mentioned that some exemplary embodiments are described as processes or methods depicted as flow charts. Although the flow charts describe the operations (or steps) as sequential processes, many of the operations (or steps) therein can be implemented in parallel, concurrently, or simultaneously. In addition, the order of the operations can be rearranged. A process can be terminated when its operations are completed, but can also have additional steps not included in the accompanying drawings; a process can correspond to a method, function, procedure, subroutine, subprogram, etc.

[0029] Example: According to a first aspect of this embodiment, a method for actively monitoring adverse drug reactions is provided, such as Figure 1 As shown, the following steps are included: S1. Generate a first mapping table based on the correspondence between drug data in a drug database and historical adverse reaction data, and construct a first search library based on the first mapping table.

[0030] Specifically, S1 includes the following steps: S11. Obtain historical adverse reaction data corresponding to all drug types in the drug database; S12, determine the drug ID corresponding to each drug type, and perform data cleaning on the historical adverse reaction data to extract the corresponding adverse reaction type; S13, constructing a first mapping table based on the correspondence between the drug ID and the adverse reaction type; S14. Construct a first search library based on the first mapping table.

[0031] In this embodiment, the historical adverse reaction data corresponding to all drug types in the drug database are first obtained, and then the obtained historical adverse reaction data are cleaned and extracted to the corresponding adverse reaction types. For example, the drug types of cardiovascular drugs in the drug database include aspirin, clopidogrel and atorvastatin, among which the historical adverse reaction types corresponding to aspirin include gastrointestinal bleeding and allergic reactions, the adverse reaction types corresponding to clopidogrel include thrombocytopenia and headache, and the adverse reaction types corresponding to atorvastatin include muscle pain and abnormal liver function. Assume that the drug ID corresponding to aspirin is determined to be B001, the drug ID corresponding to clopidogrel is B002, and the drug ID corresponding to atorvastatin is B003. Determine the adverse reaction type ID corresponding to each adverse reaction type. Assume that the adverse reaction type ID corresponding to gastrointestinal bleeding is R007, the adverse reaction type ID corresponding to allergic reaction is R001, the adverse reaction type ID corresponding to thrombocytopenia is R008, the adverse reaction type ID corresponding to headache is R009, the adverse reaction type ID corresponding to muscle pain is R010, and the adverse reaction type ID corresponding to abnormal liver function is R011. Construct a first mapping table based on the correspondence between drug ID and adverse reaction type. The obtained first mapping table includes B001 corresponding to R007 and R001, B002 corresponding to R008 and R009, and B003 corresponding to R010 and R011. The first search library is constructed based on the obtained first mapping table combined with the adverse reaction type.

[0032] In the above embodiment, by determining the drug ID corresponding to each drug type, performing data cleaning on the historical adverse reaction data, and extracting the corresponding adverse reaction type, redundant and erroneous data are effectively removed, and a first mapping table is constructed based on the correspondence between the drug ID and the adverse reaction type to ensure the accuracy and uniqueness of the mapping relationship. A first retrieval library is constructed based on the first mapping table, so that in the subsequent monitoring process, the corresponding drug information can be quickly retrieved according to the adverse reaction type, which not only improves the retrieval efficiency, but also reduces the system resource consumption, which helps to select drugs more carefully and accurately during the medication process and reduce the occurrence of adverse reactions.

[0033] S2. Generate a second mapping table based on the correspondence between the historical adverse reaction data and the historical clinical sign data, and construct a second search library based on the second mapping table.

[0034] Specifically, S2 includes the following steps: S21. Obtaining historical clinical sign data corresponding to each adverse reaction type in the historical adverse reaction data; S22, cleaning the historical clinical sign data and extracting the corresponding clinical sign types; S23, constructing a second mapping table based on the correspondence between the adverse reaction type and the clinical sign type; S24. Construct a second search library based on the second mapping table.

[0035] In this embodiment, it is assumed that the corresponding clinical sign types when the adverse reaction type is gastrointestinal bleeding include black stools, hematemesis, abdominal pain, anemia and hypotension, the corresponding clinical sign types when the adverse reaction type is allergic reaction include skin erythema, urticaria, shortness of breath, laryngeal edema and anaphylactic shock, the corresponding clinical sign types when the adverse reaction type is thrombocytopenia include skin petechiae, ecchymosis, gum bleeding and epistaxis, the corresponding clinical sign types when the adverse reaction type is gastrointestinal discomfort include nausea, vomiting, diarrhea, abdominal pain and indigestion, the corresponding clinical sign types when the corresponding clinical sign types are muscle pain include muscle tenderness, muscle weakness, increased creatine kinase and soy sauce-colored urine, and the corresponding clinical feature types when the adverse reaction type is abnormal liver function include jaundice, increased liver enzymes (such as ALT, AST), loss of appetite and nausea. Based on the corresponding relationship between each adverse reaction type and clinical feature type, a second mapping table is constructed, and a second search library is further constructed through the second mapping table.

[0036] In the above embodiment, by obtaining the historical clinical sign data corresponding to each adverse reaction type in the historical adverse reaction data, clinical signs closely related to adverse reactions can be identified, which helps to give early warning when the patient shows similar signs, so as to take preventive measures and reduce the occurrence of adverse reactions. By cleaning the historical clinical sign data and extracting the corresponding clinical sign types, the accuracy and consistency of the data are ensured. Constructing a second mapping table based on the correspondence between the adverse reaction type and the clinical sign type helps doctors better understand and determine the occurrence mechanism of adverse reactions, so as to formulate more effective prevention and treatment strategies. Constructing a second retrieval library based on the second mapping table enables doctors to quickly retrieve adverse reaction information related to current clinical signs when facing patients, so as to more accurately assess the patient's risks and formulate personalized treatment plans, thereby optimizing the clinical decision-making process.

[0037] S3. Initiate an access request to the hospital information system based on the access permission information. After the request is approved, obtain the corresponding patient's real-time drug usage data, real-time adverse reaction data, and real-time clinical sign data from the hospital information system.

[0038] Specifically, S3 includes the following steps: S31, generating corresponding access permission information based on the monitoring period and monitoring object information; S32, submitting an access application to the hospital information system based on the access permission information, and having the hospital information system review the access permission information. If the review is passed, access to the data server of the hospital information system is allowed. If the review is not passed, executing S31; S33. Obtain real-time drug usage data, real-time adverse reaction data and real-time clinical sign data from the data server of the hospital information system.

[0039] In the above embodiment, by combining the monitoring cycle and the monitoring object information to generate the corresponding access permission information, it is ensured that only users or systems with legal permissions can access the data server of the hospital information system. The permission-based access control mechanism effectively prevents unauthorized access and data leakage, and enhances the security of data access. An access application is submitted to the hospital information system based on the access permission information, and the access permission information is reviewed by the hospital information system to ensure the compliance of data access. Real-time drug use data, real-time adverse reaction data, and real-time clinical sign data are obtained from the data server of the hospital information system. The acquisition of real-time data can help medical institutions to detect potential problems in a timely manner and take measures, and also ensure the accuracy and reliability of the data.

[0040] Specifically, S31 includes the following steps: S311, setting a monitoring period based on the monitoring start time and the monitoring end time; S312, determining the basic identity information corresponding to the monitored object, and setting the corresponding access permission level based on the basic identity information; S313, generating an authority information identifier based on the monitoring period, basic identity information and access authority level; S314. Perform hash encoding on the authority information identifier based on a hash algorithm to obtain an encrypted information identification code.

[0041] In this embodiment, for example, the monitoring period is from 8:00 am on January 1, 2023 to 22:00 pm on January 31, 2023, the basic identity information corresponding to the monitored object is determined, and the corresponding access permission level is set based on the basic identity information. For example, the monitored objects include Zhang San and Li Si, and the basic identity information of Zhang San and Li Si is obtained. The basic identity information of this embodiment takes the patient number as an example. For example, the patient number corresponding to Zhang San is 001, and the patient number corresponding to Li Si is 002. The access permission level corresponding to Zhang San is high, and the access permission level corresponding to Li Si is medium. Then, the permission information identifier corresponding to Zhang San is generated as "202301_001_High", and the permission information identifier corresponding to Li Si is generated as "202301_001_High". The information identifier is "202301_002_Medium". The permission information identifier is hashed based on the hash algorithm to obtain an encrypted information identification code. This embodiment uses the SHA-256 hash algorithm for encryption processing. For example, the permission information identifier "202301_001_High" is used as input, and hash encoding is performed to obtain a string of fixed hash values ​​as the encrypted information identification code. For example, the permission information identification code corresponding to "202301_001_High" is: "9e107d9d372bb6826bd81d3542a419d61eb3f115d800c49e6a6eb3cffedb12b8a".

[0042] In this embodiment, the corresponding access permission level is set by determining the basic identity information of the monitored object, ensuring that only users or systems with corresponding permissions can access the relevant data. The permission information identifier is encrypted using a hash algorithm to further enhance the security of access control and prevent the leakage and tampering of permission information. Based on the monitoring cycle, basic identity information and access permission level, the permission information identifier is generated and hashed to obtain an encrypted information identification code, which can enable the access and use of data to be accurately recorded and tracked, and can be quickly located through the encrypted information identification code to ensure the traceability and auditability of the data. The generated encrypted information identification code can be used as a credential to access the medical information system, and information sharing and interaction can be more efficient while ensuring the security of data access.

[0043] Specifically, S32 includes the following steps: S321, sending the encrypted information identification code to the hospital information system through the corresponding communication protocol; S322, the hospital information system receives the encrypted information identification code and performs hash decoding to obtain the authority information identifier; S323, extracting the monitoring period, basic identity information and authority information from the authority information identifier; S324. Review the monitoring cycle and basic identity information in combination with the authority information. If the review is passed, access the data server of the hospital information system. If the review is not passed, execute S31.

[0044] In this embodiment, the HTTPS protocol is first configured to connect to the hospital information system, and the encrypted information identification code is sent to the hospital information system as part of the request. The server side of the hospital information system receives the encrypted information identification code, calls the built-in hash function library, and uses the same hash algorithm (SHA-256) to decode the encrypted information identification code. After successful decoding, the original permission information identifier "202301_001_High" is obtained. The permission information identifier is string segmented, and the year and month (202301), patient number (001) and permission level (High) are extracted respectively with a specific separator as the boundary. Check whether the current time is within the monitoring period, for example, check whether the current date is within January 2023, verify whether the basic identity information is consistent with the information stored in the hospital information system, and then review based on the permission information. If the review passes, access to the data server of the hospital information system is allowed to perform the corresponding data query operation. If the review fails, the permission information identifier is regenerated.

[0045] In this embodiment, the encrypted information identification code is sent through the corresponding communication protocol to ensure the security and integrity of the data transmission process. Since the encrypted information identification code is hash-coded, even if it is intercepted during the transmission process, the original permission information cannot be easily obtained, thereby effectively preventing the leakage of sensitive information. After receiving the encrypted information identification code, the hospital information system performs hash decoding to quickly restore the original permission information identifier. The decoding process is more efficient than the traditional audit method and reduces the possibility of manual intervention and errors. The monitoring cycle and basic identity information are audited in combination with the permission information to ensure that only users or systems that meet the requirements can obtain the permission to access the hospital information system data server, thereby improving the accuracy of the permission audit. If the audit fails, the access permission information is regenerated to ensure that it can self-recover and continue to operate normally in the face of errors or abnormal situations, thereby improving the reliability and stability of the system.

[0046] S4. Search the second search database based on the real-time clinical sign data, and obtain corresponding adverse reaction data based on the clinical sign data obtained by the search and the first mapping table.

[0047] Specifically, S4 includes the following steps: S41, performing data cleaning on the real-time clinical sign data to extract corresponding real-time clinical sign types; S42, matching the real-time clinical sign type with all clinical sign types in the second search library to obtain a corresponding clinical sign type; S43. Searching for the adverse reaction type corresponding to the clinical sign type based on the matched clinical sign type in combination with the second mapping table.

[0048] In this embodiment, it is assumed that the clinical sign types corresponding to the clinical sign data of patient Zhang San obtained in real time include "black stools" and "abdominal pain". First, the obtained clinical sign types are matched with the clinical sign types in the second search library. The corresponding second mapping table is called in the second search library, and the adverse reaction type corresponding to "black stools" and "abdominal pain" is obtained as "gastrointestinal bleeding" based on the called second mapping table.

[0049] In the above embodiment, by performing data cleaning on the real-time clinical sign data to extract the corresponding real-time clinical sign type, invalid, erroneous or duplicate data can be removed, the accuracy and reliability of subsequent analysis can be ensured, and the efficiency and accuracy of data processing can be improved. By matching the real-time clinical sign type with all clinical sign types in the second search library, the corresponding clinical sign type can be quickly found through an efficient search algorithm. Based on the matched clinical sign type, the corresponding adverse reaction type is searched in combination with the second mapping table, and the precise association between clinical signs and adverse reactions is achieved, which helps to accurately judge the adverse reactions that may occur in patients, so as to take corresponding preventive and therapeutic measures.

[0050] S5. Search the first search database based on the adverse reaction data, and match the retrieved drug data with the real-time drug usage data to obtain a drug matching result.

[0051] Specifically, S5 includes the following steps: S51, matching the adverse reaction type found with all adverse reaction types in the first search library to obtain a corresponding adverse reaction type; S52, searching for drug data corresponding to the adverse reaction type based on the matched adverse reaction type and the first mapping table; S53: Match the found drug data with the real-time drug ID in the real-time drug usage data to obtain a corresponding drug ID.

[0052] In this embodiment, the adverse reaction type "gastrointestinal bleeding" obtained by the search is first matched with all adverse reaction types in the first search library, and the first mapping table is called according to the matched adverse reaction type. Based on the called first mapping table, the drug ID corresponding to the adverse reaction type "gastrointestinal bleeding" is B001, and the drug type corresponding to the drug ID B001 is "aspirin".

[0053] In the above embodiment, by matching the adverse reaction type obtained by the search with all the adverse reaction types in the second search library, the accuracy and uniqueness of adverse reaction identification are ensured, which helps medical institutions to accurately understand the types of adverse reactions that patients may encounter and provide a strong basis for subsequent treatment and preventive measures. Based on the matched adverse reaction type, the corresponding drug data is searched in combination with the first mapping table to achieve a rapid association between adverse reactions and drugs that may cause the adverse reactions, which can quickly locate problematic drugs and provide important information for subsequent drug safety assessments and risk controls. The drug data obtained by the search is matched with the real-time drug ID in the real-time drug usage data to obtain the corresponding drug ID, which enables monitoring of real-time drug usage, helps to promptly discover and deal with problems in drug usage, and ensures the safety and effectiveness of patient medication.

[0054] S6. Generate an adverse reaction monitoring log based on the drug matching results and upload it to the hospital information system.

[0055] Specifically, S6 includes the following steps: S61. Determine the relevant drug ID, adverse reaction type and clinical sign type according to the drug matching result; S62. Determine the severity of the adverse reaction type; S63, generating a corresponding adverse reaction monitoring log based on the drug ID, adverse reaction type and clinical sign type; S64. Label the adverse reaction monitoring log based on the severity, and upload the labeled adverse reaction monitoring log to the hospital information system.

[0056] In this embodiment, the drug ID, adverse reaction type and clinical sign type that are related in sequence are determined according to the drug matching results to be "aspirin", "gastrointestinal bleeding", "melena" and "abdominal pain". According to industry standards, the adverse reaction "gastrointestinal bleeding" is classified as "severe". A corresponding adverse reaction monitoring log is generated. For example, the obtained adverse reaction monitoring log includes drug information and adverse reaction information, and the severity is marked as "severe" on this adverse reaction monitoring log.

[0057] In the above embodiment, the adverse reaction monitoring log is generated by combining the drug ID, adverse reaction type and clinical sign type, which enhances the transparency and traceability of adverse reaction monitoring, and helps to respond quickly and effectively when adverse reaction events occur. The adverse reaction monitoring log is marked based on the severity, and the marked log is uploaded to the hospital information system. Medical institutions can adjust treatment plans and optimize drug use rules based on the adverse reaction monitoring log, which helps medical institutions establish a more complete drug vigilance and risk management system to ensure the safety and effectiveness of patients' medication.

[0058] According to a second aspect of this embodiment, a system for actively monitoring adverse drug reactions is provided, such as Figure 2 As shown. Includes: A first search library construction module M01, used to generate a first mapping table based on the correspondence between drug data and historical adverse reaction data in the drug database and to construct a first search library based on the first mapping table; A second search library construction module M02, used to generate a second mapping table based on the correspondence between the historical adverse reaction data and the historical clinical sign data and to construct a second search library based on the second mapping table; Data access request module M03, used to initiate an access request to the hospital information system based on the access permission information, and obtain the corresponding patient's real-time drug use data, real-time adverse reaction data and real-time clinical sign data from the hospital information system after the request is approved; A first adverse reaction retrieval module M04 is used to search the second retrieval library based on the real-time clinical sign data, and obtain the corresponding adverse reaction data according to the clinical sign data obtained by the retrieval and the first mapping table; The second adverse reaction retrieval module M05 is used to search the first search library based on the adverse reaction data, and match the retrieved drug data with the real-time drug usage data to obtain a drug matching result; The monitoring log construction module M06 is used to generate adverse reaction monitoring logs based on drug matching results and upload them to the hospital information system.

[0059] Beneficial effects of this embodiment: By constructing the first mapping table and the first search library, as well as the second mapping table and the second search library, the precise association between drug data, adverse reaction data and clinical sign data is achieved, and the accuracy and efficiency of adverse reaction monitoring are improved. By cleaning the historical data, redundant and erroneous data are effectively removed, the accuracy and uniqueness of the mapping relationship are ensured, and the system resource consumption is reduced. By obtaining the drug usage data, adverse reaction data and clinical sign data of patients in real time, it is helpful for medical institutions to promptly discover potential problems and take measures, thereby improving the safety of patients' medication. Through the authority control mechanism, the security of data access is ensured, and unauthorized access and data leakage are prevented. Finally, the generated adverse reaction monitoring log and its annotations help medical institutions adjust treatment plans, optimize drug use rules, establish a more complete drug vigilance and risk management system, and ensure the effectiveness and safety of patients' medication. This embodiment significantly improves the efficiency of adverse drug reaction monitoring, reduces the incidence of adverse reactions, and ensures the safety of patients' medication.

[0060] The above specific implementation is a preferred implementation of a method and system for actively monitoring adverse drug reactions of the present invention, and is not intended to limit the specific implementation scope of the present invention. The scope of the present invention includes but is not limited to the present specific implementation. All equivalent changes made in accordance with the shape and structure of the present invention are within the protection scope of the present invention.

Claims

1. A method for actively monitoring adverse drug reactions, characterized in that: The steps include: S1, generating a first mapping table based on the correspondence between drug data and historical adverse reaction data in a drug database and constructing a first search library based on the first mapping table; S2, generating a second mapping table based on the correspondence between the historical adverse reaction data and the historical clinical sign data, and constructing a second search library based on the second mapping table; S3, initiating an access request to the hospital information system based on the access permission information, and obtaining the corresponding patient's real-time drug usage data, real-time adverse reaction data, and real-time clinical sign data from the hospital information system after the request is approved; S4, searching the second search library based on the real-time clinical sign data, and acquiring corresponding adverse reaction data according to the clinical sign data obtained by the search and the first mapping table; S5. Search the first search database based on the adverse reaction data, and match the retrieved drug data with the real-time drug usage data to obtain a drug matching result; S6. Generate an adverse reaction monitoring log based on the drug matching results and upload it to the hospital information system.

2. The method for monitoring adverse drug reactions according to claim 1, characterized in that: The S1 comprises the following steps: S11. Obtain historical adverse reaction data corresponding to all drug types in the drug database; S12, determining the drug ID corresponding to each drug type, and performing data cleaning on the historical adverse reaction data to extract the corresponding adverse reaction type; S13, constructing a first mapping table based on the correspondence between the drug ID and the adverse reaction type; S14. Construct a first search library based on the first mapping table.

3. The method for monitoring adverse drug reactions according to claim 1, characterized in that: The S2 comprises the following steps: S21, obtaining historical clinical sign data corresponding to each adverse reaction type in the historical adverse reaction data; S22, performing data cleaning on the historical clinical sign data to extract corresponding clinical sign types; S23, constructing a second mapping table based on the correspondence between the adverse reaction type and the clinical sign type; S24: construct a second search library based on the second mapping table.

4. The method for monitoring adverse drug reactions according to claim 1, characterized in that: The S3 comprises the following steps: S31, generating corresponding access permission information in combination with the monitoring period and the monitoring object information; S32, submitting an access application to the hospital information system based on the access permission information, and having the hospital information system review the access permission information. If the review is passed, access to the data server of the hospital information system is allowed; if the review is not passed, executing S31; S33. Acquire real-time drug usage data, real-time adverse reaction data and real-time clinical sign data from the data server of the hospital information system.

5. A method for monitoring adverse drug reactions according to claim 4, characterized in that: The S31 comprises the following steps: S311, setting a monitoring period based on the monitoring start time and the monitoring end time; S312, determining basic identity information corresponding to the monitored object, and setting a corresponding access permission level based on the basic identity information; S313, generating an authority information identifier based on the monitoring period, basic identity information and access authority level; S314: Perform hash encoding on the authority information identifier based on a hash algorithm to obtain an encrypted information identification code.

6. A method for monitoring adverse drug reactions according to claim 4, characterized in that: The S32 comprises the following steps: S321, sending the encrypted information identification code to the hospital information system through a corresponding communication protocol; S322, the hospital information system receives the encrypted information identification code and performs hash decoding to obtain an authority information identifier; S323, extracting the monitoring period, basic identity information and authority information from the authority information identifier; S324, review the monitoring period and basic identity information in combination with the authority information. If the review is passed, access the data server of the hospital information system. If the review is not passed, execute S31.

7. The method for monitoring adverse drug reactions according to claim 1, characterized in that: The S4 comprises the following steps: S41, performing data cleaning on the real-time clinical sign data to extract corresponding real-time clinical sign types; S42, matching the real-time clinical sign type with all clinical sign types in the second search library to obtain a corresponding clinical sign type; S43: searching for the adverse reaction type corresponding to the clinical sign type based on the clinical sign type obtained by matching and combining the second mapping table.

8. The method for monitoring adverse drug reactions according to claim 5, characterized in that: The S5 comprises the following steps: S51, matching the adverse reaction type found with all adverse reaction types in the first search library to obtain a corresponding adverse reaction type; S52, searching for drug data corresponding to the adverse reaction type based on the adverse reaction type obtained by matching and combining with the first mapping table; S53: Match the found drug data with the real-time drug ID in the real-time drug usage data to obtain a corresponding drug ID.

9. The method for monitoring adverse drug reactions according to claim 1, characterized in that: The S6 comprises the following steps: S61, determining the drug ID, adverse reaction type and clinical sign type that are related in sequence according to the drug matching result; S62. Determine the severity of the adverse reaction type; S63, generating a corresponding adverse reaction monitoring log in combination with the drug ID, the adverse reaction type and the clinical sign type; S64. Annotate the adverse reaction monitoring log based on the severity, and upload the annotated adverse reaction monitoring log to a hospital information system.

10. A drug adverse reaction monitoring system, applicable to a drug adverse reaction detection method as claimed in any one of claims 1 to 9, characterized in that: include: A first search library construction module, used to generate a first mapping table based on the correspondence between drug data and historical adverse reaction data in the drug database and to construct a first search library based on the first mapping table; A second search library construction module, used to generate a second mapping table based on the correspondence between the historical adverse reaction data and the historical clinical sign data and to construct a second search library based on the second mapping table; A data access request module is used to initiate an access request to the hospital information system based on the access permission information, and obtain the corresponding patient's real-time drug usage data, real-time adverse reaction data and real-time clinical sign data from the hospital information system after the request is approved; A first adverse reaction retrieval module is used to search the second retrieval library based on the real-time clinical sign data, and obtain the corresponding adverse reaction data according to the clinical sign data obtained by the retrieval and the first mapping table; A second adverse reaction retrieval module is used to search the first retrieval library based on the adverse reaction data, and match the retrieved drug data with the real-time drug usage data to obtain a drug matching result; The monitoring log construction module is used to generate adverse reaction monitoring logs based on drug matching results and upload them to the hospital information system.

Images